UBS Group
JBIO

UBS Group’s Jade Biosciences JBIO Stock Holding History

UBS Group’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.83M Buy
127,577
+62,555
+96% +$1.3M ﹤0.01% 4767
2026
Q1 		$914K Sell
65,022
-31,764
-33% -$460K ﹤0.01% 5619
2025
Q4 		$1.49M Buy
96,786
+76,955
+388% +$903K ﹤0.01% 5225
2025
Q3 		$171K Sell
19,831
-1,207
-6% -$9.86K ﹤0.01% 6762
2025
Q2 		$210K Buy
21,038
+20,786
+8,248% +$707K ﹤0.01% 6688
2025
Q1 		$22.2K Sell
252
-21
-8% -$1.84K ﹤0.01% 8158
2024
Q4 		$25.3K Buy
273
+92
+51% +$7.93K ﹤0.01% 7737
2024
Q3 		$13.3K Sell
181
-135
-43% -$8.71K ﹤0.01% 7597
2024
Q2 		$18.3K Sell
316
-5
-2% -$3.32K ﹤0.01% 7352
2024
Q1 		$332K Sell
321
-29
-8% -$22.1K ﹤0.01% 5503
2023
Q4 		$277K Buy
350
+30
+9% +$15.3K ﹤0.01% 5557
2023
Q3 		$152K Buy
320
+234
+272% +$127K ﹤0.01% 5553
2023
Q2 		$51.4K Sell
86
-85
-50% -$54.4K ﹤0.01% 6461
2023
Q1 		$121K Buy
+171
New +$142K ﹤0.01% 5774
2022
Q4 		– Sell
-46
Closed -$26K – 10718
2022
Q3 		$26K Buy
+46
New +$30.7K ﹤0.01% 7035
2022
Q1 		– Sell
-14
Closed -$6K – 10231
2021
Q4 		$6K Sell
14
-17
-55% -$8.6K ﹤0.01% 9249
2021
Q3 		$23K Sell
31
-28
-47% -$15.7K ﹤0.01% 7005
2021
Q2 		$47K Buy
+59
New +$47.1K ﹤0.01% 6487

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group's JBIO Position: Q2 2026 in Review

UBS Group increased its Jade Biosciences (JBIO) stake by 96% in Q2 2026, buying an estimated $1.3M and bringing the position to 127,577 shares worth $2.83M. The position accounts for ﹤0.01% of the portfolio, ranked #4767.

UBS Group first reported a position in JBIO in Q2 2021 and has held it in 18 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • UBS Group held 127,577 shares of Jade Biosciences worth $2.83M as of Q2 2026.
  • UBS Group bought 62,555 Jade Biosciences shares in Q2 2026, an estimated $1.3M.
  • Jade Biosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4767 holding.
  • UBS Group first reported a position in Jade Biosciences in Q2 2021 and has held it in 18 quarters since.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.